Stablecoin fever: 5 major stablecoins are growing crypto adoption
Increasing institutional interest and moves toward legal frameworks for stablecoins have seen the space grow, with five major projects slated to expand the market in the near future.
In the EU, the Markets in Crypto-Assets (MiCA) regulatory package is in full force and has given stablecoin issuers clear guidelines by which they can enter European markets. In the US, the STABLE Act and the GENIUS Act, which would provide rules for stablecoins, are making their way through Congress.
As a result, major payments firms like Mastercard and Visa are stepping up support for stablecoin systems, and new coins have appeared, boosting the overall market capitalization of the stablecoin market.
Here are five major stablecoin initiatives projected to grow crypto adoption.
Tether to relaunch in the US
Stablecoin giant Tether is eyeing a relaunch in the US with a dollar-based stablecoin.
Tether's USDt is already known worldwide as the largest stablecoin on the market, providing liquidity to crypto trading pairs on numerous exchanges.
However, Tether has found itself in hot water with regulators over proof of its reserves, other financial transparency and Anti-Money Laundering concerns.
In an April 30 interview with CNBC, Tether CEO Paolo Ardoino announced that the firm wants to launch a rebranded coin in the US, separate from its ubiquitous international stablecoin. 'A domestic stablecoin would be different from the international stablecoin,' he said.
The move would give Tether access to US financial markets as the latter's exposure to crypto widens under the pro-crypto administration of US President Donald Trump. Trump dabbles in the dollar with USD1
At the beginning of March, World Liberty Financial (WLFI), the cryptocurrency project tied to the Trump family, launched its dollar-backed stablecoin, USD1, on the BNB Chain and Ethereum.
According to CoinMarketCap, the coin has over $2 billion in market capitalization at publishing time.
The stablecoins follow other high-profile crypto projects that use the president's personal brand as a marketing tool, namely the TRUMP and WLFI memecoins that launched ahead of Trump's inauguration.
Trump's ability to influence stablecoin policy has led a group of US senators to call for an inquiry into his personal interests in the project, calling it a clear conflict of interest.
Custodia and Vantage Bank launch bank-issued coin on Ethereum
Two US banks, the crypto-friendly Custodia Bank and the Texas-based Vantage Bank, have entered a partnership to issue the supposed first bank-issued stablecoin in the US, UK and Europe.
On March 25, Custodia stated that it tokenized US dollar demand deposits on the Ethereum blockchain as an ERC-20 standard token called Avit.
Custodia CEO and crypto advocate Caitlin Long said that Avit is a 'real dollar' in that it tokenizes funds that customers can withdraw on demand, like checking account deposits. Stripe is testing a stablecoin product
On April 28, Stripe CEO Patrick Collison announced that his global payments platform was working on a US-dollar-based stablecoin product for use outside the US.
The move comes after it received approval to acquire stablecoin payments network Bridge in a $1-billion deal in October 2024, a deal which it completed in February 2025.
Bridge was founded by two former Coinbase executives, Zach Abrams and Sean Yu, in 2022 and competes with firms using the ubiquitous SWIFT global payments system.
The stablecoin initiative is the latest development in the firm's expanding crypto plans. After a false start on Bitcoin support in 2014, the firm began rebuilding its crypto team in earnest in 2021. On Oct. 9, 2024, the firm opened USDC support for users in 70 countries. UAE's largest bank to issue stablecoin
Abu Dhabi's International Holding Company, Abu Dhabi Developmental Holding and First Abu Dhabi Bank (FAB) partnered to launch a dirham-backed stablecoin on April 28.
According to The National, FAB — the largest bank in the UAE — will issue the stablecoin on the ADI network pending approval from the central bank.
The ADI network is a project of the ADI Foundation in Abu Dhabi, which itself is a nonprofit organization founded by Sirius International Holding, a local holding firm with a $243 billion market capitalization.
The firms claim that the stablecoin will 'have a significant impact on various industries, including finance, commerce, and trade.' Visa, SBI and Mastercard add more stablecoin support
New stablecoin issuances are picking up the pace, and payments firms, banks and financial institutions are adding support for them as well.
On April 28, international payments giant Mastercard partnered with OKX to expand its stablecoin card options, which allow cardholders to spend stablecoins through their Mastercard linked with prominent crypto firms.
Two days later, Visa announced that it partnered with Stripe and Bridge on April 30 to offer stablecoin payments on its network in Latin America, starting with Argentina, Colombia, Ecuador, Mexico, Peru and Chile.
SBI VC Trade, the cryptocurrency subsidiary of the Japanese financial conglomerate SBI, said it was preparing to add support for USDC after local regulators softened their approach to foreign stablecoins. Pending formal approval, the trading platform will be one of the first in Japan to offer cryptocurrency trading in USDC.
Regulators and payments providers worldwide are warming up to stablecoins. US lawmakers have yet to vote on the aforementioned crypto bills, but if the stablecoin frameworks pass, adoption is set to take off as firms gain access to a large financial market with clear guidelines.
Source: https://cointelegraph.com/news/major-stablecoins-growing-crypto-adoption
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13-06-2025
- Globe and Mail
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies
DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
13-06-2025
- Globe and Mail
Tyler Technologies: A Strong Contender in Government Software Solutions
Explore the exciting world of Tyler Technologies (NYSE: TYL) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of May 7, 2025. The video was published on Jun. 12, 2025. Should you invest $1,000 in Tyler Technologies right now? Before you buy stock in Tyler Technologies, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tyler Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
13-06-2025
- Globe and Mail
Why Shares of Archer Aviation Took Flight This Week
Since last Friday, shares of the electric vertical take-off and landing (eVTOL) aircraft company Archer Aviation (NYSE: ACHR) traded about 15% higher, as of the close of trading on Thursday. The company conducted more successful testing, received positive sentiment from Wall Street, and President Donald Trump's administration issued executive orders that could benefit Archer. More progress on testing Cantor Fitzgerald issued a research note earlier this week, maintaining its overweight rating on the stock and issuing a $13 price target. Analyst Andres Sheppard said the company recently conducted a successful piloted test of its Midnight aircraft. The Midnight reached a cruising speed of 125 miles per hour and an altitude of over 1,500 feet. Archer also announced Thursday that it recently completed a piloted transition flight. The company describes this flight as one that "occurs when the aircraft takes off vertically like a helicopter, accelerates forward, transitions from thrust-borne to wing-borne flight like an airplane with tilt propellers forward, before decelerating and landing vertically." On Wednesday, the Trump administration also issued several executive orders on drones, flying cars, and supersonics. Specifically, one order creates a pilot program to test eVTOLs for air taxis, cargo, and defense logistics. For Archer to eventually set up air taxis for commercial use, it will need regulators to sign off, so the Trump administration's support is a good sign. Compelling and expensive Archer has shown tremendous promise. Not only has its Midnight aircraft achieved many regulatory and operational milestones, but the company has also secured contracts with the Department of Defense through its partnership with Anduril. If commercial air taxis becomes a massive new sector, Archer will likely be one of the few companies that can quickly gobble up market share. However, the company is not yet profitable and already trades at a $6.4 billion market cap, making it tough to go all in just yet. I would start with a smaller, speculative position and build it as Archer achieves regulatory milestones and other big accomplishments. Should you invest $1,000 in Archer Aviation right now? Before you buy stock in Archer Aviation, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Archer Aviation wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
